Physician
Hematology
Dr. Sam L. Penza, MD
|
|
Give Review
Doctor Sam L. Penza, MD practices Hematology. He graduated from The Ohio State University College of Medicine. He over the years received 1 awards: "CMS Meaningful Use Stage 1 Certification". Penza is a published doctor and has 37 publications published. The lastest was: 'Mobilization of peripheral-blood progenitor cells with high-dose etoposide and granulocyte colony-stimulating factor in patients with breast cancer, non-Hodgkin's lymp...' He accepts Medicare payments and is listed with Medicare.gov.
Publications
- Atorvastatin for the Prophylaxis of Acute Graft vs. Host Disease (GVHD) in Patients Undergoing HLA-Matched Related Donor Hematopoietic Stem Cell Transplantation (HSCT).
- Examination of unplanned 30-day readmissions to a comprehensive Cancer hospital.
- Complex Karyotype Is Associated With Aggressive Disease and Shortened Progression-Free Survival in Patients With Newly Diagnosed Mantle Cell Lymphoma.
- Lower dose of antithymocyte globulin does not increase Graft-versus-host disease in patients undergoing reduced-intensity conditioning allogeneic hematopoietic stem ce...
- A phase 1 study of vorinostat maintenance after autologous transplant in high-risk Lymphoma.
- The hematopoietic stem cell transplant comorbidity index can predict for 30-day readmission following autologous stem cell transplant for Lymphoma and multiple myeloma.
- An effective mobilization strategy for Lymphoma patients after failed upfront mobilization with plerixafor.
- Aprepitant for the control of delayed nausea and vomiting associated with the use of high-dose melphalan for autologous peripheral blood stem Cell transplants in patie...
- Flavopiridol can be safely administered using a pharmacologically derived schedule and demonstrates activity in relapsed and refractory Non-Hodgkin's Lymphoma.
- Association of pre-transplantation positron emission tomography/computed tomography and outcome in mantle cell Lymphoma.
- Early versus delayed autologous stem Cell transplant in patients receiving novel therapies for multiple myeloma.
- High disease burden is associated with poor outcomes for patients with Acute myeloid leukemia not in remission who undergo unrelated donor cell transplantation.
- Oral preCancerous and malignant lesions associated with graft-versus-host disease: report of 2 cases.
- High-dose busulfan, cyclophosphamide, and etoposide does not improve outcome of allogeneic stem cell transplantation compared to BuCy2 in patients with Acute myeloid l...
- Therapy-related myelodysplasia and Leukemia occur infrequently following VP-16 priming and autotransplantation without total body irradiation.
- Radiation-free regimens result in similar outcomes of allogeneic hematopoietic progenitor Cell transplantation in patients aged >or=50 years compared to younger adults...
- Hepatic dysfunction following busulfan and cyclophosphamide myeloablation: a retrospective, multicenter analysis.
- Emotion management skills in sexually maltreated and nonmaltreated girls: a developmental psychopathology perspective.
- Busulfan levels are influenced by prior treatment and are associated with hepatic veno-occlusive Disease and early mortality but not with delayed complications followi...
- The influence of early transplantation, age, GVHD prevention regimen, and other factors on outcome of allogeneic transplantation for CML following BuCy.
- Autotransplantation following busulfan, etoposide and cyclophosphamide in patients with non-Hodgkin''s Lymphoma.
- Analysis of prognostic factors for allogeneic marrow transplantation following busulfan and cyclophosphamide in Myelodysplastic syndrome and after leukemic transformat...
- Mobilization of peripheral-blood progenitor cells with high-dose etoposide and granulocyte colony-stimulating factor in patients with breast Cancer, non-Hodgkin's lymp...
- Influence of graft-versus-host disease on outcome following allogeneic transplantation with radiation-free preparative therapy in patients with advanced Leukemia.
- Effects of chemistry, manufacturing and concentration of the dye basic fuchsin regarding its use in quantitative cytophotometry.
- Second autologous stem cell transplant for multiply relapsed Hodgkin''s Disease.
- Diffuse alveolar hemorrhage following gemtuzumab ozogamicin.
- Syngeneic vs. allotransplantation in chronic myeloid Leukemia: all's well that ends well.
- Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced Myeloid malignancies after allogeneic stem-cell transplantation.
- Higher busulfan dose intensity does not improve outcomes of patients undergoing allogeneic haematopoietic Cell transplantation following fludarabine, busulfan-based re...
- Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplanta...
- Incidence and reasons for late failure after allogeneic haematopoietic cell transplantation following BuCy2 in Acute myeloid leukaemia.
- Late mortality and relapse following BuCy2 and HLA-identical sibling marrow transplantation for chronic myelogenous Leukemia.
- Addition of infliximab to standard Acute graft-versus-host disease prophylaxis following allogeneic peripheral blood cell transplantation.
- Long-term outcome of Hodgkin Disease patients following high-dose busulfan, etoposide, cyclophosphamide, and autologous stem cell transplantation.
- High-dose melphalan versus busulfan, cyclophosphamide, and etoposide as preparative regimens for autologous stem Cell transplantation in patients with multiple myeloma.
Schools
Ohio State University College Of Medicine and Public Health
Ohio State University Hosps
Ohio State UArthur James Canc Hosps
Procedures Preformed
- Bone Marrow Transplant
- HPC Transplantation (Stem Cell Transplant)
- Plasmapheresis
Conditions Treated
- Acute Leukemia
- Anemia
- Bladder Cancer
- Breast Cancer
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
Ohio State University Hospital -
The Ohio State University College of Medicine
Hospital
-
Ohio State University Wexner Medical Center
Drug Facts
| NPI NUMBER | 1356359640 | |
| NPPES Provider LastName | PENZA | |
| NPPES Provider FirstName | SAM | |
| NPPES Provider ZIPCode | 432101280 | |
| NPPES Provider State | OH | |
| Specialty Description | Hematology | |
| Total Claim Count | 124.0 | |
| Distinct Opioid Count | 3.0 | |
| Opioid Claim Count | 71.0 | |
| Percent Opioid Claims | 57.26 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1356359640 |
| Last Name Of The Provider | PENZA |
| First Name Of The Provider | SAM |
| View All |
Similar Doctors
|
Dr. Neil C. Dunavin, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Edward B. Jamelarin, MD |
|
Dr. Ramiro Garzon, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Brent C. Behrens, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jerry T. Guy, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Michael A. Caligiuri, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
Dr. David E. Symer, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Elizabeth M. Yu, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Christina S. Wu, MD |
|
Dr. Maura L. Gillison, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Steven J. Nicol, MD |